CN119136830A - 用于治疗眼部疾病的组合物和方法 - Google Patents

用于治疗眼部疾病的组合物和方法 Download PDF

Info

Publication number
CN119136830A
CN119136830A CN202380037102.8A CN202380037102A CN119136830A CN 119136830 A CN119136830 A CN 119136830A CN 202380037102 A CN202380037102 A CN 202380037102A CN 119136830 A CN119136830 A CN 119136830A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
hvr
faba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037102.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·耶德诺克
L·泰勒
A·格罗夫
D·方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CN119136830A publication Critical patent/CN119136830A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380037102.8A 2022-04-29 2023-04-28 用于治疗眼部疾病的组合物和方法 Pending CN119136830A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336539P 2022-04-29 2022-04-29
US63/336,539 2022-04-29
PCT/US2023/066393 WO2023212719A1 (en) 2022-04-29 2023-04-28 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
CN119136830A true CN119136830A (zh) 2024-12-13

Family

ID=88519880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037102.8A Pending CN119136830A (zh) 2022-04-29 2023-04-28 用于治疗眼部疾病的组合物和方法

Country Status (10)

Country Link
US (1) US20250313614A1 (enExample)
EP (1) EP4518896A4 (enExample)
JP (1) JP2025515485A (enExample)
KR (1) KR20250006238A (enExample)
CN (1) CN119136830A (enExample)
AU (1) AU2023262202A1 (enExample)
CA (1) CA3250843A1 (enExample)
IL (1) IL316218A (enExample)
MX (1) MX2024013326A (enExample)
WO (1) WO2023212719A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184235A1 (en) * 2024-02-28 2025-09-04 Onl Therapeutics, Inc. Methods and compositions for treating glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CN116782940A (zh) * 2020-12-04 2023-09-19 安尼艾克松股份有限公司 用于治疗眼部疾病的组合物和方法

Also Published As

Publication number Publication date
AU2023262202A1 (en) 2024-10-24
KR20250006238A (ko) 2025-01-10
US20250313614A1 (en) 2025-10-09
JP2025515485A (ja) 2025-05-15
IL316218A (en) 2024-12-01
WO2023212719A1 (en) 2023-11-02
EP4518896A1 (en) 2025-03-12
EP4518896A4 (en) 2026-08-12
CA3250843A1 (en) 2023-11-02
MX2024013326A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
CN116782940A (zh) 用于治疗眼部疾病的组合物和方法
HK1201196A1 (en) Treatment of ocular disease
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
US20250313614A1 (en) Compositions and methods for treating ocular diseases
HK40121733A (en) Compositions and methods for treating ocular diseases
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (en) Compositions and methods for treating ocular diseases
CN119907685A (zh) 用于抗c1q抗体的制剂
HK1262078A1 (en) Anti-complement factor c1q fab fragments and uses thereof
HK1262078B (en) Anti-complement factor c1q fab fragments and uses thereof
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40121733

Country of ref document: HK